Cholangiocarcinoma, also known as bile duct cancer, is one of those rare diseases that previously gained little attention from the biopharma community. It has a small population and is challenging to treat. About 8,000 people in the U.S. are diagnosed each year, and most learn they have the disease at the late stages when the prognosis is poor.